MARKET NEWS

Friday Funding: Vial Looks To Evolve Clinical Drug Trials

By: James Flippin · December 02, 2022 · Reading Time: 3 minutes

Clinical Trial Switch-up

San Francisco-based startup Vial is a CRO, or contract research organization. In the life sciences space, these firms provide research services on a contract basis.

Founded in 2020, Vial aims to better organize the clinical trial process that drug companies utilize in their bids to gain FDA approval. When a new drug is developed, the clinical trial essentially determines whether it can be sold on the open market in pursuit of profit. On Wednesday, Vial announced a fundraising round of $67 million.

Room for Improvement

Clinical trials represent an ongoing challenge for biotech firms. They’re capital-intensive, time-consuming, and require specific execution. Finding the right candidates for tests is difficult. Vial aims to become a central hub that the industry can use in order to become more efficient.

Vial isn’t alone in trying to fill this niche. Since the COVID-19 pandemic, the FDA has allowed trials to be done remotely, changing the process significantly. Private equity has been flowing into the space. According to Crunchbase, the sector received over $2 billion in new funding in 2021.

Pharmacies Getting Involved

Biotech companies have a financial incentive to get through the clinical trial process as quickly as possible, in a race against the clock. Once patents expire after around 20 years, generic drugs can be made.

The change in the FDA’s rules regarding clinical trials have attracted the attention of more established companies. Walmart (WMT), CVS (CVS), and Walgreens (WBA) have all launched efforts aimed at identifying clinical trial candidates. It’s another example of how our personal information — in this instance, medical data — is an extremely valuable commodity.

Looking for more stories like this? Check out On the Money — SoFi’s one-stop-shop for news, trends, and tips!

Check it out


Please understand that this information provided is general in nature and shouldn’t be construed as a recommendation or solicitation of any products offered by SoFi’s affiliates and subsidiaries. In addition, this information is by no means meant to provide investment or financial advice, nor is it intended to serve as the basis for any investment decision or recommendation to buy or sell any asset. Keep in mind that investing involves risk, and past performance of an asset never guarantees future results or returns. It’s important for investors to consider their specific financial needs, goals, and risk profile before making an investment decision.
The information and analysis provided through hyperlinks to third party websites, while believed to be accurate, cannot be guaranteed by SoFi. These links are provided for informational purposes and should not be viewed as an endorsement. No brands or products mentioned are affiliated with SoFi, nor do they endorse or sponsor this content.
Communication of SoFi Wealth LLC an SEC Registered Investment Advisor
SoFi isn’t recommending and is not affiliated with the brands or companies displayed. Brands displayed neither endorse or sponsor this article. Third party trademarks and service marks referenced are property of their respective owners.
SOSS22120203

TLS 1.2 Encrypted
Equal Housing Lender